<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038168</url>
  </required_header>
  <id_info>
    <org_study_id>DM98-268</org_study_id>
    <nct_id>NCT00038168</nct_id>
  </id_info>
  <brief_title>Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma</brief_title>
  <official_title>Phase I/II Study of Intravenous Estramustine Phosphate Combined With Taxol in Patients With Hormone Refractory Adenocarcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I: The goal of this clinical research study is to find the highest dose of estramustine&#xD;
      phosphate administered intravenously in combination with a fixed dose of Taxol (paclitaxel)&#xD;
      that can be given safely to participants with prostate cancer who have failed to further&#xD;
      benefit from hormone treatment.&#xD;
&#xD;
      Phase II: The goal of this clinical research study is to find out if the combination of the&#xD;
      drugs estramustine phosphate and paclitaxel will shrink or control prostate cancer that has&#xD;
      not responded to hormone treatment. A second goal is to find out if the side effects of these&#xD;
      drugs can be reversed. The safety of these drugs will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the maximum tolerated dose of intravenous estramustine phosphate combined with&#xD;
      Taxol.&#xD;
&#xD;
      To estimate the complete and partial response rates to treatments with intravenous&#xD;
      estramustine phosphate combined with Taxol in the treatment of hormone-refractory&#xD;
      adenocarcinoma of the prostate.&#xD;
&#xD;
      To determine the qualitative and quantitative toxicity of the combination of intravenous&#xD;
      estramustine phosphate and Taxol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Study Completion</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Estramustine + Taxol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estramustine</intervention_name>
    <description>Intravenous dose</description>
    <arm_group_label>Estramustine + Taxol</arm_group_label>
    <other_name>Estramustine phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxol</intervention_name>
    <description>Intravenous dose</description>
    <arm_group_label>Estramustine + Taxol</arm_group_label>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologic proof of adenocarcinoma of the prostate and must have failed&#xD;
             conventional hormonal therapy.&#xD;
&#xD;
          -  Patients must have osteoblastic bone metastases. At least one osteoblastic lesion must&#xD;
             be documented by plain film. Patients with mixed or osteolytic bone metastases must&#xD;
             have a biopsy to exclude histologic variants of prostate cancer or metastasis from&#xD;
             another primary (for phase II only).&#xD;
&#xD;
          -  Patients must have evidence of progression of disease as demonstrated by 2 consecutive&#xD;
             rise in PSA (an absolute change of at least 1 ng/mL) over 4 weeks.&#xD;
&#xD;
          -  Patients on flutamide, nilutamide, or bicalutamide should be discontinued from&#xD;
             flutamide or nilutamide and bicalutamide for at least 4 weeks and 8 weeks,&#xD;
             respectively.&#xD;
&#xD;
          -  Patients must have an expected survival of at least three months and a Zubrod&#xD;
             performance status of &lt; 2 (Zubrod scale; Appendix B).&#xD;
&#xD;
          -  Patients may receive no concurrent chemotherapy or immunotherapy.&#xD;
&#xD;
          -  Patients must have castrate serum testosterone levels (&lt; 30 ng/dl). For patients who&#xD;
             are medically castrated, lutenizing hormone releasing hormone analog must continue to&#xD;
             maintain testicular suppression.&#xD;
&#xD;
          -  Patients must have adequate bone marrow function defined as an absolute peripheral&#xD;
             granulocyte count of &gt; 1,500/mm3 and platelet count of &gt; 100,000/mm3; adequate hepatic&#xD;
             function defined with a bilirubin of &lt; 1.5 mg% and SGOT (AST) &lt; 2X the upper limits of&#xD;
             normal; adequate renal function defined as serum creatinine clearance &gt; 40 cc/min&#xD;
             (measured or calculated).&#xD;
&#xD;
          -  Patients must be &gt;= 18 years old.&#xD;
&#xD;
          -  Patients may have received oral EMP or no more than one cytotoxic therapy.&#xD;
&#xD;
          -  Patients must sign a written informed consent form prior to treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with severe intercurrent infection.&#xD;
&#xD;
          -  Patients with prior exposure to Taxol.&#xD;
&#xD;
          -  Patients whose tumors contain small cell or sarcomatoid elements.&#xD;
&#xD;
          -  Patients with evidence of conduction block or active myocardial ischemia on ECG.&#xD;
&#xD;
          -  Patients with a history of prior malignancy (except noninvasive cutaneous carcinoma).&#xD;
&#xD;
          -  Patients with a history of thromboembolism.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeri Kim, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>May 29, 2002</study_first_submitted>
  <study_first_submitted_qc>May 29, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2002</study_first_posted>
  <last_update_submitted>July 31, 2012</last_update_submitted>
  <last_update_submitted_qc>July 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Estramustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

